GOZZETTI ALESSANDRO
Curriculum Vitae
Teaching activities
Completion accademic year: 2026/2027
Completion accademic year: 2025/2026
Course year: 1
First cycle degree (DM 270)
CARDIOCIRCULATORY AND CARDIOVASCULAR PERFUSION TECHNIQUES
A.Y. 2025/2026
Completion accademic year: 2024/2025
Course year: 1
First cycle degree (DM 270)
CARDIOCIRCULATORY AND CARDIOVASCULAR PERFUSION TECHNIQUES
A.Y. 2024/2025
Research
Ultime pubblicazioni:
- Corsale, A.M., Azgomi, M.S., Gigliotta, E., Di Simone, M., Pacelli, P., Cioffi, F., et al. (2026). Bone marrow immune cell composition reflects multiple myeloma progression and affects treatment response. BLOOD NEOPLASIA, 3(1) [10.1016/j.bneo.2025.100174]. - view more
- Zent, C.S., Tiacci, E., Kreitman, R.J., Tadmor, T., Tallman, M.S., Wörmann, B.J., et al. (2026). Updated consensus guidelines for the diagnosis and management of patients with hairy cell leukemia (HCL) and HCL-variant. BLOOD [10.1182/blood.2025032757]. - view more
- Frustaci, A.M., Galitzia, A., Lucignano, M., Appio, L., Olivieri, J., Sanna, A., et al. (2026). Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice. HAEMATOLOGICA, 111(1), 206-218 [10.3324/haematol.2025.287799]. - view more
- Gozzetti, A., Pacelli, P., Caroni, F., Raspadori, D., Bestoso, E., Antonioli, E., et al. (2026). MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM. BRITISH JOURNAL OF HAEMATOLOGY [10.1111/bjh.70448]. - view more
- Gay, F., Buda, G., Petrucci, M.T., Bolli, N., Cea, M., Derudas, D., et al. (2026). Refining the role of selinexor in multiple myeloma: strategic use in a shifting treatment landscape. ESMO OPEN, 11(3) [10.1016/j.esmoop.2025.106054]. - view more